Nausea News and Research RSS Feed - Nausea News and Research

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.
Actavis reports positive results from ceftazidime-avibactam Phase III studies in cIAI patients

Actavis reports positive results from ceftazidime-avibactam Phase III studies in cIAI patients

Actavis plc today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections. [More]
Survey finds low awareness about risks of cognitive side effects following surgery

Survey finds low awareness about risks of cognitive side effects following surgery

Postsurgical cognitive side effects can have major implications for the level of care, length of hospital stay, and the patient's perceived quality of care, especially in elderly and fragile patients. A nationwide survey of Swedish anesthesiologists and nurse anesthetists has found there is low awareness of the risks of cognitive side effects following surgery. [More]
Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen (NASDAQ: AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. [More]
Treatments that involve neck manipulation may be linked with strokes

Treatments that involve neck manipulation may be linked with strokes

Treatments that involve neck manipulation may be associated with strokes, although this association is not proven, according to an American Heart Association Scientific Statement written by lead author Dr. Jose Biller of Loyola University Medical Center and other stroke experts. [More]
Cochrane review finds little evidence to support use of sleep or wake drugs for shift workers

Cochrane review finds little evidence to support use of sleep or wake drugs for shift workers

Shift workers are taking drugs to help them stay awake or get to sleep despite weak evidence for their benefit, according to a new Cochrane review. [More]
Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. [More]
Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS). [More]
New molecular test kit predicts survival outcomes in kidney cancer patients

New molecular test kit predicts survival outcomes in kidney cancer patients

Researchers and doctors at the Institute of Bioengineering and Nanotechnology (IBN), Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) have co-developed the first molecular test kit that can predict treatment and survival outcomes in kidney cancer patients. This breakthrough was recently reported in European Urology, the world's top urology journal. [More]
Researchers uncover 3D structure of neuroreceptor

Researchers uncover 3D structure of neuroreceptor

Neurons are the cells of our brain, spinal cord, and overall nervous system. They form complex networks to communicate with each other through electrical signals that are carried by chemicals. [More]
Study confirms benefit of surgical treatment for migraines

Study confirms benefit of surgical treatment for migraines

Dr. Oren Tessler, Assistant Professor of Clinical Surgery at LSU Health Sciences Center New Orleans School of Medicine, is part of a team of plastic and reconstructive surgeons who report a high success rate using a method to screen and select patients for a specific surgical migraine treatment technique. [More]
GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S. [More]
FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use. [More]
EMA CHMP adopts positive opinion for Janssen’s IMBRUVICA to treat CLL and MCL

EMA CHMP adopts positive opinion for Janssen’s IMBRUVICA to treat CLL and MCL

Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorisation for IMBRUVICA (ibrutinib) in the European Union. [More]
Taiwan researchers develop new optical device to detect early complication of diabetes sooner

Taiwan researchers develop new optical device to detect early complication of diabetes sooner

A group of researchers in Taiwan has developed a new optical technology that may be able to detect an early complication of diabetes sooner, when it is more easily treated. If the device proves safe and effective in clinical trials, it may pave the way for the early detection and more effective treatment of this complication, called diabetic autonomic neuropathy, which is common among people with both Type 1 and Type 2 diabetes. [More]
EMA recommends full marketing approval for IMBRUVICA in the European Union

EMA recommends full marketing approval for IMBRUVICA in the European Union

Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA (ibrutinib) in the European Union. [More]
Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). [More]
FDA approves Targiniq ER to treat severe pain

FDA approves Targiniq ER to treat severe pain

Today, the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. [More]
Wake Forest Baptist shares tips to help avoid heat-related illnesses

Wake Forest Baptist shares tips to help avoid heat-related illnesses

Working out when it's hot isn't such a hot idea. Just ask Bret Nicks, M.D., associate professor of emergency medicine at Wake Forest Baptist Medical Center. [More]
Zydelig gets FDA approval for treatment of patients with three types of blood cancers

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. [More]
Pilot study shows that anti-cancer drug can activate hidden HIV

Pilot study shows that anti-cancer drug can activate hidden HIV

A pilot study by HIV researchers from Aarhus University and Aarhus University Hospital in Denmark has shown that an anti-cancer drug can activate hidden HIV. [More]